Takeda director Paulus Stoffels files Form 3

TAKEDA PHARMACEUTICAL CO LTD filed an initial Form 3 reporting that Paulus Stoffels is a director of the company.

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD filed an initial Form 3 reporting that Paulus Stoffels is a director of the company. The filing shows no reported transactions in the company’s securities and no derivative positions, serving purely as a baseline disclosure of his insider status.

Key Terms

Form 3, reporting person, director

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [ { "name": "Stoffels Paulus""

director regulatory

""is_director": 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Paulus Stoffels Form 3 filing for TAKEDA (TAK) show?

The Form 3 shows that Paulus Stoffels is a director of TAKEDA PHARMACEUTICAL CO LTD. It is an initial beneficial ownership statement and, in this case, reports no transactions or derivative positions in the company’s securities.

Are there any buy or sell transactions reported in this TAK Form 3?

No transactions are reported in this Form 3 for TAKEDA PHARMACEUTICAL CO LTD. The transaction summary shows zero buys, zero sells, zero derivative exercises, and no gifts or restructurings, indicating a purely administrative insider-status filing.

What insider role does Paulus Stoffels have at TAKEDA (TAK)?

Paulus Stoffels is identified as a director of TAKEDA PHARMACEUTICAL CO LTD. The Form 3 confirms his status as a reporting person under insider rules, without showing any accompanying trades or derivative holdings in this particular filing.

Does the TAKEDA (TAK) Form 3 disclose any derivative securities for Paulus Stoffels?

The Form 3 derivative summary is empty, so it does not disclose any derivative securities for Paulus Stoffels. This means no options, warrants, or similar instruments are reported for him in this specific insider ownership statement.

What is the net buy or sell direction in this TAK Form 3 filing?

The transaction summary indicates a neutral net buy/sell direction, with zero shares bought or sold. This reflects that the filing contains only status information for Paulus Stoffels at TAKEDA, with no trading activity reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 11:31 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stoffels Paulus

(Last) (First) (Middle)

C/O TAKEDA PHARMACEUTICAL COMPANY

1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU

(Street)

TOKYO 103-8668

(City) (State) (Zip)

JAPAN

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/24/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Kate Huleatt, by power of attorney, for Paul Stoffels	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)